Bio-Techne reported fiscal Q2 2026 revenue of $295.9 million, flat year-over-year on both a reported and organic basis, with Adjusted EPS increasing 10% to $0.46. Performance was mixed, with strength in large pharma (low double-digit growth) and international markets (China mid-single digits, APAC ~20%) offset by softness in US academia and emerging biotech. A significant temporary headwind came from two large cell therapy customers receiving FDA Fast Track designations, which reduced GMP reagent demand by over 30%. Despite the flat top line, Adjusted Operating Margin expanded 100 basis points to 31.1% due to disciplined cost management and the Exosome Diagnostics divestiture. Management highlighted that their four strategic growth verticals (Cell Therapy, Proteomics, Spatial Biology, and Diagnostics) now represent 47% of revenue and are growing at an upper-teens CAGR. Guidance for Q3 indicates organic growth will remain consistent with Q2 (flat) due to lingering customer-specific headwinds, but underlying business trends are improving, with expectations for mid-single-digit growth excluding these factors and a full-year target of 100 basis points of operating margin expansion.
| Metric | Value | Change |
|---|---|---|
| Total Revenue | $295.9 million | Flat YoY |
| Organic Revenue Growth | 0% | N/A |
| Adjusted EPS | $0.46 | +10% YoY |
| Adjusted Operating Margin | 31.1% | +100 bps YoY |
| Adjusted Gross Margin | 68.5% | -200 bps YoY |
| Protein Sciences Sales | $215.1 million | -1% Organic |
| Diagnostics & Spatial Biology Sales | $81.2 million | +3% Organic |
| China Growth | Mid-single digits | Positive |
| APAC Growth | ~20% | Strong |
Management emphasized the resilience of their Cell Therapy vertical despite a 50% drop in GMP reagents from two specific customers. Excluding these two accounts, the cell therapy business grew nearly 30%, and the pending full acquisition of Wilson Wolf (growing 20% organically) positions the company for a significant inflection point in fiscal 2027 when the Fast Track headwinds lap. This signals that the current revenue stagnation is a temporary timing issue rather than a structural demand problem.
Geographic diversification is becoming a primary growth driver, with China delivering its third consecutive quarter of growth (mid-single digits) and APAC ex-China growing nearly 20%. Management attributes this to China's 15th five-year funding plan prioritizing life sciences and increased activity in CDMOs/CROs. This reduces reliance on the currently soft US academic market and aligns with global R&D spending shifts.
Bio-Techne is successfully executing a 'pivot to growth' strategy, with four strategic verticals now comprising 47% of total revenue, up from 32% in fiscal 2020. These verticals delivered an upper-teens CAGR over the past five years. Specifically, the Spatial Biology franchise saw a 'meaningful acceleration in bookings' for the Comet platform (nearly 40% growth), indicating strong future revenue momentum and instrument placement.
Operational discipline remains a key strategic pillar, as evidenced by the 100 basis point expansion in Adjusted Operating Margin to 31.1% despite flat revenue growth. Management achieved this through structural streamlining and a 240 basis point reduction in SG&A as a percentage of revenue. This leverage allows them to continue investing in R&D (7.8% of revenue) while maintaining high profitability, supporting the 'durable moats' thesis.
Management provided a clear roadmap for end market recovery, citing a '6-month lag' for biotech funding to translate into tool spending. With biotech funding having 'rebounded meaningfully in 2025' and Q4 funding showing significant increases, management expects a gradual recovery in customer sentiment throughout calendar 2026. This provides a tangible timeline for investors to monitor for a demand inflection.
Gross Margin Compression: Adjusted gross margin declined 200 basis points year-over-year to 68.5%, driven by 'unfavorable product and customer mix.' Management noted that lower-margin instruments and specific OEM customers impacted profitability. While they expect this to 'gradually improve,' the shift in mix poses a risk to near-term earnings quality if the reagent business does not rebound as quickly as anticipated.
Biotech and Academic End Market Weakness: Despite optimism about future funding, the current reality is that emerging biotech revenue declined mid-single digits and US academia declined low single digits. Management admitted that 'funding uncertainty has influenced customer behavior,' and the 6-month lag for funding to impact revenue creates a prolonged period of sluggish demand that could persist into the second half of the fiscal year.
Customer Concentration Risk: The company's performance remains heavily leveraged to two large cell therapy customers. The FDA Fast Track designation for these customers created a 400 basis point headwind in Q2 and is expected to impact Q3 by 300 basis points. This high level of concentration creates volatility and visibility challenges, making it difficult to predict growth until these specific dynamics normalize.
Q3 Guidance Softness: Management guided for Q3 organic growth to be 'consistent with Q2' (flat), citing a 300 basis point headwind from cell therapy and a 100 basis point headwind from OEM order timing. This indicates that the anticipated recovery is being pushed out, potentially delaying the revenue inflection point until Q4 or fiscal 2027, which could test investor patience.
Overall: Management maintained a disciplined and confident demeanor throughout the call, acknowledging the 'challenging but stabilizing' market environment while emphasizing the strength of the underlying business. They were transparent about specific headwinds, particularly regarding the two cell therapy customers, but used detailed data points to argue that the core business is accelerating. The tone shifted from cautious in the prepared remarks regarding current numbers to optimistic in the Q&A when discussing the future outlook and end market recovery.
Confidence: HIGH - Management provided specific metrics to support their outlook, such as the 30% underlying growth in cell therapy (excluding the two large customers) and the 6-month lag estimate for biotech funding. They reaffirmed full-year margin guidance despite revenue headwinds, demonstrating confidence in their operational leverage.
Consistent with Q2 (Flat)
~300 bps from cell therapy, ~100 bps from OEM timing
Mid-single digits
+100 basis points
Hedging & Uncertainty: Management frequently used temporal qualifiers to manage expectations regarding the timing of the recovery. Phrases like 'gradual improvement,' 'stabilizing but still challenging,' and 'positioning this end market for improvement' were used to describe the biotech and academic sectors. They also used specific exclusionary hedging, constantly referring to results 'excluding the two largest cell therapy customers' to highlight underlying strength while acknowledging the reported weakness. This pattern suggests they are confident in the long-term trajectory but cautious about promising an immediate turnaround in the next quarter.
Our disciplined focus on productivity and cost management remains a key driver of our operating margin expansion. - Kim Kelderman, CEO
We expect this headwind to moderate slightly in Q3... before moderating further in our fourth quarter and then being completely out of our year-over-year comparison in fiscal 2027. - James T. Hippel, CFO
Typically, the delay of the funding coming trickling through in life science tools is six months. - Kim Kelderman, CEO
The team delivered strong second-quarter execution in a stable market, with improved biotech funding as well as further progression towards more favorable NIH funding outcomes... - James T. Hippel, CFO
We remain excited about the FDA Fast Track designation awarded to our largest cell therapy customers. - James T. Hippel, CFO
Analyst Sentiment: Analysts were focused on the 'growth cadence' and the timing of the recovery, pressing management on when the underlying strength would translate into reported growth. There was skepticism regarding the gross margin decline and the sustainability of margin expansion given the mix shift towards instruments.
Management Responses: Management responses were detailed and data-driven, frequently breaking down growth rates to exclude specific headwinds (e.g., 'excluding the two largest cell therapy customers') to demonstrate underlying health. They defended the margin trajectory by attributing declines to temporary mix issues and reaffirmed their guidance for the full year.
Analysts probed for clarity on the 'underlying growth' rate, asking if the company could achieve mid-single-digit growth excluding the specific customer headwinds. Management confirmed this was the correct way to view the business.
There was significant discussion regarding the gross margin decline, with analysts asking for the drivers of the 'unfavorable mix.' Management explained it was due to instrument strength and lower-margin OEM orders, which they expect to reverse.
The impact of AI on demand was raised, with management viewing it as a tailwind for complex molecule manufacturing.
Analysts asked for details on the China performance, seeking to understand why Bio-Techne is outperforming peers. Management cited local funding plans and CDMO strength.
The timing of the biotech recovery was a key topic, with management reiterating the '6-month lag' thesis and pointing to positive Q4 funding data.
Bio-Techne is currently in a transition period where strong underlying business fundamentals are being obscured by significant, temporary headwinds. The company is executing well on margin expansion (100 bps to 31.1%) and seeing robust growth in strategic verticals like Spatial Biology (Comet bookings +40%) and international markets (APAC +20%). However, the stock is likely to remain range-bound until the specific revenue headwinds from the two Fast Track cell therapy customers (impacting growth by 300-400 bps) lap in fiscal 2027. The guidance for flat growth in Q3 suggests the immediate catalyst is delayed. Investors should look for confirmation that the biotech funding recovery is translating into orders in the second half of the calendar year. The valuation support comes from the durable portfolio and high margins, but multiple expansion requires a return to sustained revenue growth.
Management noted that biotech funding 'rebounded meaningfully in 2025' and saw a significant increase in Q4 calendar 2025. They estimate a 6-month lag for this funding to translate into life science tool spending, implying a recovery starting in late calendar 2026.
Appropriation bills in the House and Senate include a 1% NIH budget increase and maintained indirect funding rates, which is 'far more supportive of academic research than originally feared.' This provides stability to a previously soft end market.
China's 15th five-year funding plan prioritizes life sciences. Combined with increased M&A and licensing activity and strong CDMO performance, this is driving mid-single-digit growth for Bio-Techne, outperforming the broader market.
Management cited positive trends in M&A and licensing activity within the biotech sector as a leading indicator for improved end market health and future demand for R&D tools.